Summary. We develop a tractable, although highly idealized, mathematical model related to carcinogenesis. This is based on the notions that cancer is largely due to the accumulation of mutations and that a general mutagen might increase the rates of all of these. The formulation and consequences are a further development of the Armitage-Doll model, both in terms of background cancer and that due to specific mutagenic exposures. The consequences regarding age-time patterns of excess cancer are simple to derive and represent, having characteristics largely independent of parameter values. It is indicated that these conform remarkably well to observations from cohort studies of the A-bomb survivors, miners with prolonged exposure to radon, and cigarette smokers who stopped smoking at various ages.
Introduction
We offer some mathematical considerations regarding age-time patterns of cancer to be anticipated from specific acute or prolonged mutagenic exposures. A primary aim is to provide guidance for analyses of cohort data. It is particularly challenging to carry out and interpret such analyses for prolonged exposures, and even for acute exposures it is difficult to distinguish between effects of age at exposure, time since exposure, and attained age.
Carcinogenesis is complicated, and we prefer not to think of our formulation as a mathematical model for this in any detail. There are, however, some plausible idealized aspects allowing interesting mathematical development. These are based simply on the notion that a cancer is largely due to the accumulation of mutations in a cell, and that a general mutagen might increase the rates of all of these. The most notable aspect of the results is provision of possible insights into age-time patterns of risk that are largely independent of parameter values in the detailed mathematical formulation.
The formulation and results are a further development of the Armitage and Doll (1954) multistage model that has for 50 years captured the imagination of statisticians and biologists interested in the age patterns of cancer rates. When considering observed cancer rates without regard to specific causes, the appeal is a possible reason why for most cancers, and for most of lifetime, there is the remarkable tendency for cancer rates to increase as a power of age.
Many others have, as here, considered the extension of the multistage model to allow for specific carcinogenic exposures. Some of this work is considered further in the Discussion section, particularly that of Whittemore and Keller (1978) , Whittemore (1977) , Day and Brown (1980) , and Ohtaki (1981) , but some brief comment at this point may be useful.
A primary emphasis has been on formulations where a given carcinogen can affect only one or two of the stage transitions. There seem to have been several reasons for this, one being that the role of multiple mutations was not realized several decades ago, and the term "stages" was often thought of in a more functional sense (e.g. initiation, promotion, progression) than here. In that interpretation of the multistage model, it was natural to be interested in whether a carcinogen seemed to act at an "early stage" or a "late stage". In multistage terminology our formulation is very different in considering that exposure to a general mutagen can affect the rate of whatever "transition", i.e. the next of several possible mutations, is being awaited by the cell. However, some work did not impose the restriction that a carcinogen can affect only very few of the stage transitions, leading to results closer to ours. At any rate, the formulation here, with explicit use of considerations arising where "stages" correspond specifically the accumulation of mutations, is a somewhat novel focus and does suggest assumptions rather different than usually made. Pierce and Mendelsohn (1999) considered a closely related formulation for the acute radiation exposures of A-bomb survivors followed up by the Radiation Effects Research Foundation (RERF) in Hiroshima and Nagasaki. Perhaps the most important thing learned from the follow-up of the A-bomb survivors is that an acute exposure at even an early age increases cancer rates for many decades, probably for all of life. This would not be expected if the radiation exposure directly induced cancers, and in fact it was not anticipated since this was -and often still is -the mechanism mainly considered. Under the mechanism considered by Pierce and Mendelsohn (and here) , the effect of an acute radiation exposure is to cause mutations and hence put some cells one step (or more) ahead of where they would have been in the lifelong accumulation of these, hence increasing cancer rates for all remaining lifetime. Pierce and Mendelsohn found that the implications of this conform well to the age-time patterns for most radiation-related solid cancers. These results, in concert with other more empirical developments [Kellerer and Barclay (1992) , Pierce, et al (1996) ], are leading to substantial reinterpretation of descriptions of the excess cancer, with more emphasis on attained age and less on age at exposure or time since exposure. The initial aim of the present research was to directly extend the Pierce-Mendelsohn results to prolonged
exposures, but what emerged was rather different than expected. As often happens, the process of solving a more general problem led to a better approach, even to the simpler one.
In the following section we indicate the basic ideas of the mathematical formulation and present the main result. The section following that discusses further some matters raised by the main results. The penultimate section provides application of the results to three settings: the A-bomb survivor data, lung cancer of miners exposed to radon, and the effects of cessation of cigarette smoking.
General formulation and result
We consider that a stem cell becomes malignant when it has accumulated a specified collection of k mutations, or one of several such collections. Formally, we make the idealization that prior to malignancy there is no clonal expansion or stem cell death, so that until malignancy a cell's progeny always consists of a single stem cell: the 'same' stem cell in terms here. However, an aspect of the model allows implicitly, to an extent, for such expansion. The term 'mutation' can mean any cellular change that transcends cell division.
Independently in each cell, the accumulation of mutations is taken as a very general -but without the exposure under consideration, age-homogeneous -Poisson process whose description requires some elaboration. The next few paragraphs describe our model for the occurrence of mutations in the background process without the mutagenic exposure.
First, all results in this paper are asymptotic and we should clarify what is meant by this.
Our results pertain to the age rate at which an individual cell becomes malignant, with the rate of occurrence of malignancy in the considered organ or organs being the rate per cell multiplied by the relevant number of stem cells. The asymptotics pertain to an individual cell, as the mutation rates uniformly approach zero, or equivalently as age decreases into the extreme left tail of the distribution of ages at which the cell becomes malignant. The chance that a given cell is not malignant by age a is Poisson process, with the rates depending on the state of the cell but not otherwise on age.
Although this age-homogeneity of the background process is a primary assumption for results as given, it is indicated in the next section how they could be modified to depart from this.
The Poisson process just described and assumed here is both biologically more specific, in focusing on mutations, and mathematically more general, in not assuming the fixed sequence ; 1, 2, r r k λ = ! , than the Armitage-Doll multistage model. However, it remains true that under our model malignancy rates will asymptotically increase as age to the ( 1) st k − power. We note that although it is well known that this pattern holds for many cancers over most of life, there is usually some decrease in the log-log slope at ages over 80-85 years.
There are many reasons to expect this. In the first place, the increase of cancer rates with age for a general population will differ in this sense from that for a more homogeneous collection of persons. That is, individual heterogeneity in lifestyle and other susceptibility to cancer, along with selection within a general population as age increases, will lead to such a result.
Moreover, there are likely biological reasons for some age inhomogeneity of mutation rates, not included in the idealized model. In these regards, our view is that it may be more useful to restrict the age range for interpretation of results here than to complicate the model to allow for such departures.
Aside from the clonal expansion issue, and a certain type of age inhomogeneity, both discussed later, the above assumptions are not intended to be highly restrictive in relation to some idealization of modern concepts of carcinogenesis. 
Biologically, we have in mind that all the mutation rates discussed above are so modified.
The exposure thus changes the age-homogeneous background process into a non-agehomogeneous one. To simplify notation we will take { ( )} ( )
, but the modifications required for the nonlinear case will be clear.
Our main result is that under these assumptions the ratio of age-specific malignancy rates for exposed and unexposed cells, that is the relative risk, is asymptotically given by
where D(a) is the cumulative dose by age a. This asymptotic approximation is excellent for mutation rates compatible with human cancer rates (with k less than 10 or so) and becomes even better if, as is natural for most needs, one does not require that the value of β in equation (1) be precisely the value defined in the mutation rates. The terms in the expansion of the (k-1) st power in equation (1) correspond to the exposure causing, in the same cell, 0,1, 2, , 1 k − ! mutations prior to the last one, and the final factor corresponds to the carcinogen causing the last of the k mutations. It will be seen in the examples that the effect of this final term can be substantial. For acute exposures this term introduces a spike in the RR at the age of exposure, but as discussed below, for cancer rates this is smoothed out by the variable time between malignancy and cancer.
It is useful to give special attention to the form after exposure ends, namely
where D is total dose. A notable feature of (2) is that this RR does not depend on time since exposure or age at exposure. The linear approximation indicated by equation (2) is adequate, with some adjustment of β , unless the value of RR exceeds 3 or 4, which is uncommon in applications. Thus the result in equation (2) is quite insensitive to the value of k provided that β is correspondingly adjusted.
The derivation of equation (1) is remarkably simple if we first consider the more usual formulation where transitions occur at fixed rates λ r , r = 1, … , k , rather than allowing these to depend on the history of the cellular process. As noted, this leads to the classical result that the background rate of malignancy per stem cell is asymptotically
A key fact underlying all results here is that for an exposed cell the process on the transformed age scale
is the same as for an unexposed cell. That is, for an exposed cell at every age e prior to the a of equation (3) 
the product of equation (3) expressed in terms of * a and the differential element * / da da .
The relative risk given by equation (1) We now show that for our more general formulation equations (3) and (4) 
, so that the ratio is still given by equation (1). Here µ , which is the same in both expressions, is a typically complicated function of rates of specific mutations, determined by the detailed specification of the model, but it does not depend on age.
Let O specify the entire sequence, for 1, , 1 
Asymptotically, considering first an unexposed cell, the first ratio in each term is given by equation (3), which we now write as
The second ratio is asymptotically unity since, as noted at the beginning of this section, on the cellular basis both the numerator and denominator are very near one. Thus we have that asymptotically
The same argument applies on the transformed age scale, so that All work in this area gives at least passing attention to some latent period between the occurrence of a malignant cell and either diagnosis or mortality. This can be particularly important, though, in interpretation of equation (1) due to the final factor there acting only during the exposure period. Many biological processes must transpire during the latent period, e.g. clonal expansion, support of the clone by angiogenesis and other processes, and overcoming natural defense mechanisms aiming to deal with the malignant cell. Not only is there some variable time required for these processes, but there is no doubt a substantial chance that they will not complete and there will be no cancer from that malignancy.
Moreover, this chance of completion and the distribution of time required probably depends on the organ involved, on hormonal activity, and other factors including age.
For simplicity we will here ignore age dependencies in these post-malignancy processes, but generalization to allow them is straightforward. Write f(t) for the density of time from malignancy to cancer given that the processes complete, and π for the probability that they complete. Then the cancer rates take approximate form
where ( ) m ⋅ denotes either of equations (3) or (4) with the substitution of µ discussed above,
Although we ordinarily use equation (7) for numerical computations, we have found that the simpler smoothing of the RR given by equation (1) usually provides an adequate approximation. The further approximation of using a constant latent period can be adequate when both numerator and denominator vary smoothly with t over most of the support of ( ) f t .
Further comments on result
In most epidemiological studies focus is on the relative risk rather than the excess absolute risk (EAR), since the former is easier to estimate and describe, but for the A-bomb survivors there has recently been substantial attention to the EAR [Pierce, et al (1996) ]. Following an acute exposure of dose D , the EAR in our results is given by the difference of equations (4) and (3),
where we use µ as introduced following equation (4). Pierce and Mendelsohn (1999) derived directly the first term of the indicated expansion, without consideration of equation (4) and the expansion itself. A large part of their interest was on the observation that descriptions of the EAR for solid cancers of A-bomb survivors show little effect of age at exposure or time since exposure [Pierce, et al (1996) )]. They showed not only that the leading term is as indicated when the exposure causes the th r mutation, 1, , r k = ! , with probability (1 ) r r p D λ β ∝ + , but that the term is independent of age at exposure only if r r p λ ∝ , 1, , r k = ! . In particular, none of the r p could then be zero, which is relevant to considerations raised in the Introduction. The further terms of the expansion in equation (8) correspond to the exposure causing 2, 3, … mutations in the same cell. For multiple or prolonged exposures these multiple-hit events become more important, at least in principle, and our initial approach was to derive directly their individual effects on the EAR , following
Pierce and Mendelsohn. It was our noting that these correspond to the expansion indicated in equation (8) that led to the much simpler argument used in this paper. Both equation (8) and its RR counterpart, equation (2), have important implications for interpretation of the A-bomb survivor data, to which we return in the following section.
The change of age scale argument, replacing a by
, is suggested by our formulation of the effect of a general mutagen, but is probably important in considerations beyond the specific model considered here. We note that the primary result of equation (1) follows from assuming only that the change of age scale argument applies, for whatever reason, and that background cancer rates increase as a power of age, again for whatever reason. Since the latter result is seen very generally (although not perfectly) in population cancer rates, it could be said that to a large extent the usefulness of equation (1) hinges only on the validity of the change of age scale argument. By this we mean that in the exposure scenario, the age-specific cancer rates on the age scale
are given by the same function of * a as are the background rates as a function of a. Note that this means the effect of an acute exposure is to make the cell suddenly "older" by a dose-dependent increment, in terms relevant to the carcinogenesis process. In experimental radiation biology the notion of "accelerated aging" has had some traditional prominence, and although the endpoint was taken as mortality to any cause the primary interest was on cancer. In terms related to prolonged exposures, Pike, et al (1983) suggested that for breast cancer the Armitage-Doll result might apply better on a transformed age scale corresponding to the number of menstrual cycles.
It is not necessary for equation (1) that radiation exposure might cause some long-lasting instability in a cell, resulting in increased mutation rates for some rather long period of time after exposure has ended. The same result of equation (1) can be used for such situations by defining ( ) d a not at the dose rate at age a, but a measure of the instability effect extending beyond exposure. That is, basically, the mathematics is essentially the same for an acute exposure followed by an instability period caused by it, and for a prolonged exposure under the formulation of this paper.
All our main results are based on the asymptotic approximation given by equation (3), and question has been raised about the adequacy of this [Moolgavkar (1978 and elsewhere) ].
In an appendix are given computationally simple exact formulas for the rates of equations (3) and (4), but these depend on the individual values of the ' s λ and thus are not very useful for the primary aims here. However, these formulas are useful for evaluation of the adequacy of the asymptotic approximations, which we consider in the appendix. We note that almost never would one care about the exact numerical relation between mutation rates and cancer rates at a given age, as approximated by equations (3) and (4). Rather, the aim is to understand the variations with age, and to some extent dose, of cancer rates and relative risks.
Our conclusions in this regard, supported in the appendix, are that there will virtually never be any serious limitations of main results along the lines of this paper due specifically to inaccuracy of the asymptotic approximations employed.
In our view the major aspect of the modern view of carcinogenesis not explicitly included in the idealized formulation here pertains to intermediate clonal expansion. That is, during the process of accumulation of mutations, a cell may obtain some growth advantage in the sense that daughter cells that would ordinarily differentiate become capable of cell division. It does not seem likely to us that this aspect can be incorporated exactly while maintaining the simplicity of mathematical development. But we believe that at least modest clonal expansion is, to some approximation, accommodated by the assumption that mutation rates can depend arbitrarily on the mutational history of the cell. That is, we can consider that the mutation rate for a clone is proportional to the size of the clone, and if the expansion is due to previous mutations then the adaptiveness of mutation rates to some extent deals with the matter. We note that our model applies exactly if, as an approximation, clonal expansion prior to full malignancy is considered only to occur immediately upon the ( 1)
Note further that in a model involving several mutations, clones of interest are unlikely to become really large, since when a clonal cell obtains a further mutation it is effectively removed from the clone and starts a new one.
The results can be generalized to allow for a certain type of non-age-homogeneity in background rates. The background model of the paper has a randomly determined r λ in affect at age a . Suppose that background rate for unexposed (and exposed) cells is multiplied by an arbitrary function ( ) s a , representing age-specific variation in sensitivity to spontaneous mutations. Such a generalization is probably necessary for cancer in organs strongly influenced by hormonal activity, and for most cancers when results for very young or very old ages are of interest. Then on the transformed age scale , and the same arguments as used in the paper show that , the main point being that the RR now depends on age at exposure e. We will not pursue this generalization in the examples, but note that for the A-bomb survivor setting it is useful for the types of cancer excluded in the analysis here.
Examples 4.1 A-bomb Survivor Data
The data used here pertain to cancer incidence during 1958-94, from the follow-up by RERF.
Documentation of similar data on cancer mortality and incidence, and the basic statistical approach, are given in Pierce, et al (1996) and Thompson, et al (1994) . For the class of cancers considered here there are about 8,000 cases for the current follow-up, of which about 400 are estimated to be related to radiation exposure. We provide an empirical description of the excess relative risk (ERR = RR-1) per unit dose, along with a fit to the data of equation (2), modified with the approximation of a fixed latent period, in form
. Results are insensitive to the choice of 0 t , taken here as 8 years. Random latent periods on, say (0,15) t ∈ give essentially the same results since the follow-up begins 12 years after exposure; note that the 8 years used
here is not to represent a minimal latent period but a central value of the distribution. Higher order terms in the expansion of the RR are negligible, and more generally the observed ERR is very linear in dose.
Semi-parametric relative risk regression is used to estimate the age-specific ERR without explicit estimation of background rates. Hence model consequences related to equations (3) and (4) are not used here. Since the leading term of equation (2) We follow Pierce and Mendelsohn (op cit) in considering the class of major, non-sexspecific cancers, excluding also thyroid cancer: namely cancers of the stomach, lung, liver, colon, rectum, gallbladder, pancreas, bladder and esophagus. The age-time patterns for thyroid cancer are very distinctive, and it is thought that radiation-related female breast cancer exhibits a special age-at-exposure effect. Pierce and Mendelsohn (op cit) made a thorough analysis regarding conformance to a model similar to that here, with attention to background rates, concluding that the restriction to the class of cancers indicated above is advisable. More complicated models, incorporating more than age effects, would be required for some cancers. . There is no statistically significant lack of fit to the model (P > 0.5). In terms of the change of age scale argument, these results suggest that exposure to 1 D = Sv causes an expected number of mutations roughly equivalent to those otherwise accumulated in about 7 years time. That is, the estimated ERR/Sv is about 0.6 at age 60, and with the Pierce-Mendelsohn estimate 5.3 k = the estimate of β from equation (2) is about 7.
Although this may provide some useful rough perspective, more careful consideration must account for the large sex difference in the ERR ignored here. The sex ratio in the ERR is similar to the reciprocal of that in background rates, suggesting that the excess absolute risk depends little on sex; and hence that radiation largely acts additively with whatever causes the sex difference in background rates. This is discussed in Pierce and Mendelsohn (op cit). The very good fit seen in Figure 1 actually obscures some of the value of considerations of this paper. For solid cancers in general, and more limited follow-up than here, the agedecrease of the ERR for those exposed at ages greater than 20 years has not been (as here) statistically significant. This has led to the primary interpretation of the data in terms of ageconstant ERR's , except for those exposed as children, but with an effect of age at exposure considered quite important. See, for example, Pierce, et al (1996) . It has only recently begun to emerge that an alternative interpretation is viable, in terms of risks depending mainly on attained age, rather than on age at exposure. Kellerer and Barclay (1992) suggested such an interpretation purely on empirical grounds, but at the time this did not have a major influence because many felt that an age-at-exposure effect was more biologically plausible than an attained-age effect. Pierce, et al (1996) noted that the lack of age-at-exposure effect was clearer in description of absolute, rather than relative, risks. The results of Pierce and Mendelsohn (1999) , and of this paper, indicate that there may be reasons to expect the risk to depend mainly on age, rather than on age at exposure. Kai, Luebeck, and Moolgavkar (1997) analyzed earlier published A-bomb survivor data on a each of a more limited number of cancer types, using a two-stage model where the ERR depends primarily on time since exposure. We have applied that model to the class of cancers considered here, using the follow-up through 1987 as in the Kai, et al (op cit) paper. The fit is rather similar to that of the model here, but in our assessment marginally poorer. The comparison is best done in terms of absolute, rather than relative, excess rates and would take too much development to present here.
Underground Miners Exposed to Radon
Two committees of the National Research Council (1988 Council ( , 1999 and also a National Cancer
Institute working group, Lubin, et al (1994 Lubin, et al ( , 1995 have done extensive analysis of pooled data on lung cancer from several large cohorts of underground miners exposed to radon.
Because exposures were prolonged, the description of age-time patterns of excess risk has been challenging, but substantial progress has been made. A primary characteristic of the descriptive modeling has been to relate the age-specific ERR to the dose within each of several "windows" of time prior to the age at risk, meaning that time since exposure has been a primary focus. The models considered also allow for a general decrease of the ERR with attained age, and the selected one an effect of exposure duration aside from accumulated dose. That used here is referred to as the exposure-age-duration model, in Table 3-3 of National Research Council (1999), which differs only in minor changes of parameter values from that presented on page 821 of Lubin, et al (1995) .
The approach illustrated in Figures 2.1-2 .3 is to graph the age-time pattern of ERR given by this descriptive model, for several typical exposure scenarios, and compare to this the results of equation (1), adapted as in equation (7) to allow for a random latent period. The dose rate is taken in terms of the conventional measure for the descriptive model, something
called WLM/year. We have not attempted to fit our model to the actual data (not publicly available), which seems unnecessary for our purposes. There are 3 choices involved in implementing the model: the values of k and β , and a distribution for the latent period.
Results are insensitive to the value of k, chosen here as 6, and β was chosen based on more exposure scenarios than shown here. In contrast to the previous example, the choice of a distribution for the latent period is here important, since we are interested in cancer rates during the exposure period. The distribution chosen here for the latent period was as follows, the mean of which is similar to that obtained in another analysis discussed below: The primary effect of the distribution of the latent period pertains to the final factor in equation (1), the effect of the exposure causing the final mutation. Considering the plots, the rapid increase in the ERR a few years after start of exposure, and the correspondingly rapid decrease ending 15 years after exposure ends, are largely the result of lagging and smoothing the effect of the exposure causing the final mutation. The noticeable change in the decline at 15 years after the end of exposure is where the effect of that final factor has disappeared, and the ERR then decreases roughly as 1/age. Although there are some minor systematic differences between the empirical description and the model prediction, the correspondence is remarkable. The empirical description, evolving from earlier developments in National Research Council (1988), was quite difficult to obtain without guidance regarding what to expect, and is subject to considerable statistical error. It is possible that with something to focus on in terms of its possible inadequacy some improvements could be made in the description. Luebeck, et al (1999) fitted a very different two-stage model for one of the cohorts involved, analysis in which a primary feature was an apparent radiation effect on the rate of clonal expansion in addition to its effect on mutation rates. Although such an effect cannot be evaluated within our formulation, the results seen here suggest that such novel considerations may not be necessary to explain the data.
Effects of Cessation of Cigarette Smoking
The American Cancer Society follows up a cohort of about a million persons in regard to lung cancer mortality and cigarette smoking. Halpern, Gillespie, and Warner (1993) present in their Table 4 age-specific lung cancer death rates for non-smokers, continuing smokers, and those who stopped smoking at various ages, ratios of which are plotted as the points in Figure 3 . We note that the follow-up used is only from 1982-88, so the age-variation is largely that for different birth cohorts. The age-specific rates for nonsmokers are quite linear on a log-log plot, with slope 1 5 k − = . The curves in Figure 3 are computed according to equation (1), incorporating a fixed latent period 0 8 t = years, with 6 k = , and 0.9 d β = during the smoking ages assumed to begin at 18 years. There is substantial time lag between cessation of smoking and evaluation of cancer risk, and the role of the latent period is less important than in the previous example. Taking 0 5 t = improves the fit slightly, but the larger value was taken to conform to the previous examples. The value of d β was chosen for an overall best fit to the points in the plot. Results are insensitive to the value of k . There is no doubt statistically significant lack of fit, but to evaluate this would require more detailed analysis. However, it is remarkable that such a simple model with essentially only one parameter could predict the risk patterns this well. ∼ for some or all values of r, Whittemore and Keller (1978) , Day and Brown (1980) , and others later, However, Ohtaki (1981 Ohtaki ( , 1985 did capitalize on this simplification, and obtained results in the direction of those reported here. In terms of our development, he considered the simplified process we refer to in deriving equation (3), although in line with previous workers he did not explicitly consider the transition rates r λ to be related to accumulation of mutations. Thus he did not consider that the rates r λ would likely depend on the mutational state of the cell. He did allow for the generalization to the special non-age-homogeneous background cancer processes referred to at the end of Section 3. Using a classical exact result that we consider in the Appendix, that used by Armitage (1953) to derive the original Armitage-doll result, he proceeded to obtain an asymptotic approximation that is essentially our equation (4) with an additional correction term. In a sense he thereby re-derived the Armitage-Doll approximation, along with generalization and refinement of it, whereas we more simply use the standard Armitage-Doll result and the change of age scale to obtain equation (4). Ohtaki did not explicitly consider the relative risk formula of our equation (1), but the primary mathematical distinction between his results and ours is that he did not consider the much more general stochastic model in which mutation rates can depend arbitrarily on the mutational history of the cell.
Although we do not want to consider details of carcinogenesis, one point should be made. Some of the mutations considered to be involved, for example proto-oncogene changes, act dominantly whereas others, for example alterations of tumor suppressor genes, act recessively. In this regard, it is our view that the mutations of each of the two alleles in the recessive case should be counted separately towards the accumulation of the k required mutations.
We conclude with some discussion of our attitude towards the value of results such as here, and about mathematical modeling more generally. Carcinogenesis is very complicated, and a formulation such as used here ignores not just details but generally important aspects.
However, science is not primarily the analysis of complexity. As pointed out in Pierce and idealized, not attempting to reflect many of the actual complexities of the process, or even of broadly considered data. What is important about a model is that it be useful, rather than that it reflect a complex reality all that faithfully; indeed its usefulness is often inversely related to its complexity. It may provide new insights into data, providing a useful framework for further thought, and suggest interesting consequences that can be verified more directlythus perhaps transcending the validity of the model.
In particular, we think that one would almost never want to fit to observed data, for descriptive purposes as opposed to evaluating a model, something as simple as equation (1).
But there is need for guidance in descriptive analyses, which are not easily done even for acute exposures and become truly daunting for prolonged exposures. For example, seldom is there the opportunity for the concerted efforts employed during the past 15 years on joint analyses of the radon-exposed miners data. We think most would agree with us that the best aim is some hybrid approach involving empirical description along with what seems useful from mathematical modeling. Further, the most important issues often involve interpretation of descriptions, where one is faced with the need to sort out causality in the presence of too many highly correlated age-time-dose covariables.
In such a hybrid approach, it may usually be best to focus on implications of the relative risk formula of equation (1), with less attention to the corresponding implications for background and absolute excess rates. It is important to deal adequately with background rates, e.g. by semi-parametric approaches, and the simple form considered here is seldom suitable for this. On the other hand, the relative risk implications are substantially more robust, and at any rate should seldom be used directly for descriptive purposes.
In these endeavors, idealized models more complex than here, that can be fitted to a wide range of age-time patterns by suitable choice of parameters, may have some appeal; but to us they seem of rather limited value. Unless there is substantial a priori knowledge of the parameter values, such models themselves have little predictive ability. They also lead to major concern with identifiability of detailed parameters, which is not an issue in the approach here. The primary strength of results such as equation (1) is that they suggest characteristic age-time patterns that are remarkably independent of the parameter values involved.
result provides much more insight, but the exact result is useful for evaluating the adequacy of the asymptotics. Moolgavkar, in (1978) and other papers, has seriously questioned the adequacy of the asymptotic results. He pointed out, for the example below, that there can be substantial error regarding cancer rate for given ages, and also through analytical considerations that for large enough mutation rates, or equivalently for large enough ages, the cancer rates depart from the log-log linearity of the asymptotic approximation. His conclusion was that the approximation is inappropriate for most practical applications. We now indicate why our conclusions are very different.
Moolgavkar considered 7 k = with transition rates λ of: 1, 2, 3, 34, 70, 80, 90 all times 4 10 − . As indicated by Moolgavkar, for these transition rates the Armitage-Doll approximation overestimates cancer rates by 17%, 27%, and 37% at ages 40, 60, and 80. The heterogeneity of transition rates is an important factor: about 1/3 of the error here is due to the size of the rates, and 2/3 is due to their heterogeneity. That is, the Armitage-Doll approximation (which depends only on the geometric mean of the transition rates) has about 1/3 the error indicated above if the ' s λ are taken as all equal to the geometric mean of those used here.
However, the interpretation of the approximation error indicated above should be guided by considering Figure A1 . The exact malignancy rates being approximated vary by a factor of about 400 on age range 30 to 85. Relative to that variation, the approximation error is small and is fairly constant since the errors vary only by a factor of 3 on that age range. Most of the approximation error cancels in computing the RR, so that equation (1) of the text has maximum error of only around 3% for doses such that RR is on the order of 5. This error is virtually eliminated if the β in equation (1) is allowed to depart slightly from the value used to define the mutation rates.
Aside from the Moolgavkar example, we have done extensive calculations for k in the range 5-7, and mutation rates -with varying degrees of heterogeneity -commensurate with observed cancer rates for 7 9
10 10 − stem cells. The results have been similar to those given above for the Moolgavkar example. Additionally, although the exact malignancy rate in principle "levels off" for sufficiently large age, there is no appreciable departure from log-log linearity in such examples even at ages of several hundred years. One would see this phenomenon in reasonable age ranges if k were taken very large, but the correspondingly large mutation rates commensurate with cancer rates would be biologically implausible.
Ordinarily, the Armitage-Doll approximation and results as in this paper are not intended for approximating, with any precision, cancer rates that correspond to given mutation rates, but rather for understanding the age-time patterns of cancer. For such purposes, at least for human cancer rates, the error in the approximations used is negligible, most certainly in relation to how seriously one should take the precise consequences of such idealized models.
In our view, the adequacy of the Armitage-Doll approximation, although of some interest, is not much of an issue. A more serious concern is the very common view that mutation rates would have to be unreasonably large to explain observed cancer rates, if as many as 5-7 mutations were required for a cancer. Although there is indeed some tension between mutation rates and cancer rates in this sense, the calculations used to make the point are often rather misguided.
Although many rather arbitrary choices must be made to explore this more adequately, the following examples are of some value. Suppose that all mutations occurred at the same rate µ per cell cycle, and could occur in any order so that the first has rate kµ , the second rate . This is indeed at least an order of magnitude larger than "spontaneous" mutation rates, although there is the issue that much cancer is caused by things that might not be considered in assessing "spontaneous" mutation rates.
This calculation assumes, however, that the 6 required mutations must occur at uniquelyspecified gene loci. If the 6 required mutations could occur at any of 12, or 18, loci then the required value of µ would drop to A serious problem with all these calculations, though, is that they assume that any malignant cell will develop to a cancer, which seems highly implausible. On the other hand, the calculations do not explicitly allow for clonal expansion, although as noted there is a close connection between mutation rates for a clone and the elevated mutation rates as just considered. The issue of multi-mutation models allowing for compatibility of mutation rates and cancer rates deserves serious attention. However, we think that the calculations just given may indicate that the tension between these is less severe than many believe.
For our model where the ' r s λ depend on which mutations have already occurred in the cell, it is feasible to compute the exact cancer rate provided all the details of the model specification are made -which is certainly not our intention in use of the results. Using equation (5) product of factors, each of which is the probability that a particular mutation occurs first among those waiting to occur. For either an exposed or unexposed cell, each of these probabilities is the ratio of the rate of the mutation considered to the sum of the rates of those mutations that might next occur.
Finally, we note that Aalen (1995) has considered time homogeneous Markov processes defined on a state space, which more abstractly generalize our background cancer model while still allowing for asymptotic development similar to that here. In the more general models the inter-event times remain exponentially distributed, but what we have referred to as the state of a cell, and as the nature of state changes at event times, is more general. It could be that there are biological considerations about accumulation of mutations in a cell that we have not considered, such as delayed repair, which could be dealt with using that more general asymptotic theory.
